Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have been barriers to more widespread use by patients.
Mark Bertolini, ex-CEO of Aetna, proposed that employers continue to contribute to employees’ insurance, but instead of enrolling them in a group plan, allow them to select an individual plan that fits their needs.
Better pay and benefits have stabilized employee turnover at U.S. hospitals, leading to significant decreases in turnover rates for nurses, non-physician clinical staff, and physicians.
The American Diabetes Association has issued a guidance statement that cautions against using compounded versions of popular GLP-1 diabetes and weight-loss drugs such as Wegovy and Zepbound.